article thumbnail

STAT+: In a rare move, FDA threatens to fine a company for failing to report clinical trial results

STAT

In a July 19 letter , the FDA warned Light Sciences Oncology about its failure to post study results about a prostate treatment to the database, ClinicalTrials.gov. After receiving the FDA letter, Light Sciences posted results on Aug. After receiving the FDA letter, Light Sciences posted results on Aug.

FDA 94
article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Sodium oxybate — which in the late 1980s was marketed to bodybuilders and then became known as GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In 2020, the FDA-approved indication was expanded to include those patients who suffer from cataplexy.

FDA 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Opinion: STAT+: The PATCH Act’s approach to securing medical devices actually gives malicious actors a blueprint

STAT

In August 2013, the FDA made news when it issued cybersecurity guidance for medical devices.

FDA 88
article thumbnail

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

pharmaphorum

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Lucentis (ranibizumab) for leading causes of blindness, raising the prospect of a cheaper treatment option for US patients. The post FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis appeared first on.

FDA 72
article thumbnail

Trial of Jazz’ cannabis drug in glioblastoma will start next year

pharmaphorum

Aside from chemotherapy the only improvements to treatment in recent years have included Roche’s VEGF-targeted antibody Avastin (bevacizumab), given a green light by the FDA in 2009, although it was subsequently rejected in Europe on the grounds of a lack of evidence for its efficacy.

article thumbnail

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims is the first to be fully interchangeable with the originator product. The post Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod appeared first on.

FDA 59
article thumbnail

The Active Ingredient Stands Alone

The FDA Law Blog

Koblitz — One of the most important questions FDA has to answer is whether a given product is appropriately characterized as a drug, biologic, device, food, cosmetic, or something entirely different. FDA further defined the term “protein” so that it includes any peptide product that has an amino acid sequence greater than 40 amino acids.

FDA 95